论文部分内容阅读
目的评价施普善(Cerebrolysin,脑活素)治疗急性期缺血性卒中的临床有效性和安全性。方法研究对象为经磁共振成像或CT确诊为一侧颈动脉系统的缺血性卒中,且神经功能缺损(NIH)评分在8~22分的患者。施普善组(144例)接受施普善50 ml静脉滴注,共10天;对照组(140例)接受非施普善的常规治疗。结果与对照组比较,施普善组患者NIH评分的改善分值和改善率除在治疗后第3天时无显著差异外,在治疗后第112、1、28天时均有显著差异。两组患者的生活能力状态评分均有改善;与对照组比较,施普善组患者生活能力状态评分的改善分值和改善率在治疗后28天时与对照组均有显著差异。结论施普善能改善急性缺血性脑卒中患者的神经功能缺损,是一种安全有效的药物。
Objective To evaluate the clinical efficacy and safety of Cerebrolysin in the treatment of acute ischemic stroke. Methods Subjects were diagnosed as ischemic stroke on one side of the carotid artery by magnetic resonance imaging or CT, and patients with a neurological deficit (NIH) score of 8-22. Spptoprost group (n = 144) received intravenous infusion of 50 ml popristin for 10 days, while control group (n = 140) received conventional treatment with non-prader. Results Compared with the control group, the improvement score and improvement rate of NIH score of the patients in the Shippusen group were significantly different at the 112th, the 1st and the 28th days except for the third day after the treatment. The scores of living status in both groups were improved. Compared with the control group, the scores and improvement rate of living ability status score of patients in the control group were significantly different from those in the control group at 28 days after treatment. Conclusion Sputum can improve neurological deficits in patients with acute ischemic stroke and is a safe and effective drug.